Literature DB >> 26031376

Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study.

Roderick Tung1, Marmar Vaseghi1, David S Frankel2, Pasquale Vergara3, Luigi Di Biase4, Koichi Nagashima5, Ricky Yu1, Sitaram Vangala6, Chi-Hong Tseng6, Eue-Keun Choi5, Shaan Khurshid2, Mehul Patel7, Nilesh Mathuria7, Shiro Nakahara8, Wendy S Tzou9, William H Sauer9, Kairav Vakil10, Usha Tedrow5, J David Burkhardt4, Venkatakrishna N Tholakanahalli10, Anastasios Saliaris11, Timm Dickfeld11, J Peter Weiss12, T Jared Bunch12, Madhu Reddy13, Arun Kanmanthareddy13, David J Callans2, Dhanunjaya Lakkireddy13, Andrea Natale4, Francis Marchlinski2, William G Stevenson5, Paolo Della Bella3, Kalyanam Shivkumar14.   

Abstract

BACKGROUND: The impact of catheter ablation of ventricular tachycardia (VT) on all-cause mortality remains unknown.
OBJECTIVE: The purpose of this study was to examine the association between VT recurrence after ablation and survival in patients with scar-related VT.
METHODS: Analysis of 2061 patients with structural heart disease referred for catheter ablation of scar-related VT from 12 international centers was performed. Data on clinical and procedural variables, VT recurrence, and mortality were analyzed. Kaplan-Meier analysis was used to estimate freedom from recurrent VT, transplant, and death. Cox proportional hazards frailty models were used to analyze the effect of risk factors on VT recurrence and mortality.
RESULTS: One-year freedom from VT recurrence was 70% (72% in ischemic and 68% in nonischemic cardiomyopathy). Fifty-seven patients (3%) underwent cardiac transplantation, and 216 (10%) died during follow-up. At 1 year, the estimated rate of transplant and/or mortality was 15% (same for ischemic and nonischemic cardiomyopathy). Transplant-free survival was significantly higher in patients without VT recurrence than in those with recurrence (90% vs 71%, P<.001). In multivariable analysis, recurrence of VT after ablation showed the highest risk for transplant and/or mortality [hazard ratio 6.9 (95% CI 5.3-9.0), P<.001]. In patients with ejection fraction <30% and across all New York Heart Association functional classes, improved transplant-free survival was seen in those without VT recurrence.
CONCLUSION: Catheter ablation of VT in patients with structural heart disease results in 70% freedom from VT recurrence, with an overall transplant and/or mortality rate of 15% at 1 year. Freedom from VT recurrence is associated with improved transplant-free survival, independent of heart failure severity.
Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ablation; Ventricular tachycardia

Mesh:

Year:  2015        PMID: 26031376      PMCID: PMC4549209          DOI: 10.1016/j.hrthm.2015.05.036

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  35 in total

1.  Management of ventricular tachycardia in the setting of a dedicated unit for the treatment of complex ventricular arrhythmias: long-term outcome after ablation.

Authors:  Paolo Della Bella; Francesca Baratto; Dimitris Tsiachris; Nicola Trevisi; Pasquale Vergara; Caterina Bisceglia; Francesco Petracca; Corrado Carbucicchio; Stefano Benussi; Francesco Maisano; Ottavio Alfieri; Federico Pappalardo; Alberto Zangrillo; Giuseppe Maccabelli
Journal:  Circulation       Date:  2013-02-25       Impact factor: 29.690

2.  Real-time integration of MDCT-derived coronary anatomy and epicardial fat: impact on epicardial electroanatomic mapping and ablation for ventricular arrhythmias.

Authors:  Carine F van Huls van Taxis; Adrianus P Wijnmaalen; Sebastiaan R Piers; Rob J van der Geest; Martin J Schalij; Katja Zeppenfeld
Journal:  JACC Cardiovasc Imaging       Date:  2013-01

3.  Epicardial ventricular tachycardia ablation a multicenter safety study.

Authors:  Frédéric Sacher; Kurt Roberts-Thomson; Philippe Maury; Usha Tedrow; Isabelle Nault; Daniel Steven; Meleze Hocini; Bruce Koplan; Lionel Leroux; Nicolas Derval; Jens Seiler; Matthew J Wright; Laurence Epstein; Michel Haissaguerre; Pierre Jais; William G Stevenson
Journal:  J Am Coll Cardiol       Date:  2010-05-25       Impact factor: 24.094

4.  Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy.

Authors:  Luigi Di Biase; Pasquale Santangeli; David J Burkhardt; Rong Bai; Prasant Mohanty; Corrado Carbucicchio; Antonio Dello Russo; Michela Casella; Sanghamitra Mohanty; Agnes Pump; Richard Hongo; Salwa Beheiry; Gemma Pelargonio; Pietro Santarelli; Martina Zucchetti; Rodney Horton; Javier E Sanchez; Claude S Elayi; Dhanunjay Lakkireddy; Claudio Tondo; Andrea Natale
Journal:  J Am Coll Cardiol       Date:  2012-07-10       Impact factor: 24.094

5.  Late potentials abolition as an additional technique for reduction of arrhythmia recurrence in scar related ventricular tachycardia ablation.

Authors:  Pasquale Vergara; Nicola Trevisi; Annalisa Ricco; Francesco Petracca; Francesca Baratto; Manuela Cireddu; Caterina Bisceglia; Giuseppe Maccabelli; Paolo Della Bella
Journal:  J Cardiovasc Electrophysiol       Date:  2012-04-04

6.  Influence of clinical and procedural predictors on ventricular tachycardia ablation outcomes: an analysis from the substrate mapping and ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial (SMASH-VT).

Authors:  Roderick Tung; Mark E Josephson; Vivek Reddy; Matthew R Reynolds
Journal:  J Cardiovasc Electrophysiol       Date:  2010-02-01

7.  Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study.

Authors:  Hildegard Tanner; Gerhard Hindricks; Marius Volkmer; Steve Furniss; Volker Kühlkamp; Dominique Lacroix; Christian DE Chillou; Jesús Almendral; Domenico Caponi; Karl-Heinz Kuck; Hans Kottkamp
Journal:  J Cardiovasc Electrophysiol       Date:  2009-07-28

8.  Functional pace-mapping responses for identification of targets for catheter ablation of scar-mediated ventricular tachycardia.

Authors:  Roderick Tung; Nilesh Mathuria; Yoav Michowitz; Ricky Yu; Eric Buch; Jason Bradfield; Ravi Mandapati; Isaac Wiener; Noel Boyle; Kalyanam Shivkumar
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-02-14

9.  Reduction in inappropriate therapy and mortality through ICD programming.

Authors:  Arthur J Moss; Claudio Schuger; Christopher A Beck; Mary W Brown; David S Cannom; James P Daubert; N A Mark Estes; Henry Greenberg; W Jackson Hall; David T Huang; Josef Kautzner; Helmut Klein; Scott McNitt; Brian Olshansky; Morio Shoda; David Wilber; Wojciech Zareba
Journal:  N Engl J Med       Date:  2012-11-06       Impact factor: 91.245

10.  Elimination of local abnormal ventricular activities: a new end point for substrate modification in patients with scar-related ventricular tachycardia.

Authors:  Pierre Jaïs; Philippe Maury; Paul Khairy; Frédéric Sacher; Isabelle Nault; Yuki Komatsu; Mélèze Hocini; Andrei Forclaz; Amir S Jadidi; Rukshen Weerasooryia; Ashok Shah; Nicolas Derval; Hubert Cochet; Sebastien Knecht; Shinsuke Miyazaki; Nick Linton; Lena Rivard; Matthew Wright; Stephen B Wilton; Daniel Scherr; Patrizio Pascale; Laurent Roten; Michala Pederson; Pierre Bordachar; François Laurent; Steven J Kim; Philippe Ritter; Jacques Clementy; Michel Haïssaguerre
Journal:  Circulation       Date:  2012-04-04       Impact factor: 29.690

View more
  93 in total

1.  Recurrent ventricular tachycardia after cardiac sympathetic denervation: Prolonged cycle length with improved hemodynamic tolerance and ablation outcomes.

Authors:  Justin Hayase; Veronica Dusi; Duc Do; Olujimi A Ajijola; Marmar Vaseghi; Jay M Lee; Jane Yanagawa; Nir Hoftman; Sha'Shonda Revels; Eric F Buch; Houman Khakpour; Osamu Fujimura; Yuliya Krokhaleva; Carlos Macias; Julie Sorg; Jean Gima; Geraldine Pavez; Noel G Boyle; Kalyanam Shivkumar; Jason S Bradfield
Journal:  J Cardiovasc Electrophysiol       Date:  2020-06-30

2.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

Review 3.  Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials.

Authors:  Sean D Pokorney; Daniel J Friedman; Hugh Calkins; David J Callans; Emile G Daoud; Paolo Della-Bella; Kevin P Jackson; Kalyanam Shivkumar; Samir Saba; John Sapp; William G Stevenson; Sana M Al-Khatib
Journal:  Heart Rhythm       Date:  2016-04-02       Impact factor: 6.343

4.  Predictive Score for Identifying Survival and Recurrence Risk Profiles in Patients Undergoing Ventricular Tachycardia Ablation: The I-VT Score.

Authors:  Pasquale Vergara; Wendy S Tzou; Roderick Tung; Chiara Brombin; Alessandro Nonis; Marmar Vaseghi; David S Frankel; Luigi Di Biase; Usha Tedrow; Nilesh Mathuria; Shiro Nakahara; Venkat Tholakanahalli; T Jared Bunch; J Peter Weiss; Timm Dickfeld; Dhanunjaya Lakireddy; J David Burkhardt; Pasquale Santangeli; David Callans; Andrea Natale; Francis Marchlinski; William G Stevenson; Kalyanam Shivkumar; William H Sauer; Paolo Della Bella
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-12

5.  Catheter Ablation of Ventricular Tachycardia: Moving Beyond Palliation?

Authors:  Nilesh Mathuria
Journal:  Tex Heart Inst J       Date:  2016-10-01

Review 6.  Catheter Ablation of Ventricular Tachycardia.

Authors:  Nilesh Mathuria
Journal:  Tex Heart Inst J       Date:  2018-06-01

7.  Cardiac sympathetic activation circumvents high-dose beta blocker therapy in part through release of neuropeptide Y.

Authors:  Jonathan D Hoang; Siamak Salavatian; Naoko Yamaguchi; Mohammed Amer Swid; Hamon David; Marmar Vaseghi
Journal:  JCI Insight       Date:  2020-06-04

8.  Prognostic significance of ventricular tachycardia clustering after catheter ablation in non-ischemic dilated cardiomyopathy.

Authors:  Francesco Santoro; Andreas Metzner; Leonie Scholz; Natale Daniele Brunetti; Christian-H Heeger; Andreas Rillig; Bruno Reissmann; Christine Lemeš; Tilmann Maurer; Thomas Fink; Osamu Inaba; Naotaka Hashiguchi; Karl-Heinz Kuck; Feifan Ouyang; Shibu Mathew
Journal:  Clin Res Cardiol       Date:  2018-10-22       Impact factor: 5.460

Review 9.  Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.

Authors:  Amir AbdelWahab; John Sapp
Journal:  Curr Cardiol Rep       Date:  2017-09-13       Impact factor: 2.931

10.  Targeted stellate decentralization: Implications for sympathetic control of ventricular electrophysiology.

Authors:  Una Buckley; Kentaro Yamakawa; Tatsuo Takamiya; J Andrew Armour; Kalyanam Shivkumar; Jeffrey L Ardell
Journal:  Heart Rhythm       Date:  2015-08-14       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.